Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2001

01-03-2001 | Original Article

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

Authors: Henriette Gourdeau, Lucie Bibeau, France Ouellet, Dominique Custeau, Louise Bernier, Terry Bowlin

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2001

Login to get access
Metadata
Title
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity
Authors
Henriette Gourdeau
Lucie Bibeau
France Ouellet
Dominique Custeau
Louise Bernier
Terry Bowlin
Publication date
01-03-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800000223

Other articles of this Issue 3/2001

Cancer Chemotherapy and Pharmacology 3/2001 Go to the issue

Original Article

A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule

Original Article

Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives α-lapachone and β-lapachone

Original Article

Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy

Original Article

Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics

Letter to the Editor

UFT-induced haemolytic anaemia

Clinical Trial Report

Typhlitis (neutropenic enterocolitis) after a single dose of vinorelbine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits